Alzinova

Alzinova AB is a biopharmaceutical company dedicated to developing active and passive immunotherapies for the treatment of Alzheimer's disease. The company was founded in 2011 by scientists from the University of Gothenburg, Sweden, following the invention of the unique technology platform AβCC. The AβCC technology specifically stabilizes disease-driving oligomers of the peptide amyloid-beta (Aβ), enabling the development of therapies that can modify the disease.